Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence

Rheumatology International

Volumn 32, Issue 1, 2012, Pages 5-13

  Goh, Leslie ^a   Jewell, Teresa ^a   Laversuch, Catherine ^a   Samanta, Ash ^b  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Anti TNF; Infections; Orthopaedic surgery; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR;

BACTERIAL ARTHRITIS; DRUG WITHDRAWAL; ELECTIVE SURGERY; HUMAN; JOINT SURGERY; ORTHOPEDIC SURGERY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN INFECTION; SUBCUTANEOUS TISSUE INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; ORTHOPEDIC PROCEDURES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; SURGICAL WOUND INFECTION; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84857109425     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2040-6     Document Type: Review

References (65)

1. A Finckh HK Choi F Wolfe 2006 Progression of radiographic damage joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment Ann Rheum Dis 65 1192 1197 16540549 10.1136/ard.2005.049338 1:STN:280:DC%2BD28vnvFKqtw%3D%3D (Pubitemid 44277395)
2. L Massardo SE Gabriel CS Crowson WM O' Fallon EL Matteson 2002 A population based assessment of the use of orthopedic surgery in patients with rheumatoid arthritis J Rheumatol 29 52 56 11824971 (Pubitemid 34041858)
3. E Da Silva MF Doran CS Crowson WM O'Fallon EL Matteson 2003 Declining use of orthopaedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment Arthritis Rheum 49 216 220 12687513 10.1002/art.10998 (Pubitemid 36418280)
4. JF Fries CA Williams D Morfeld G Singh J Sibley 1996 Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies Arthritis Rheum 39 616 622 8630111 10.1002/art.1780390412 1:CAS:528:DyaK28XivVegtLY%3D (Pubitemid 26118040)
5. G Louie MM Ward 2010 Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007 Ann Rheum Dis 69 868 871 19581279 10.1136/ard.2009.112474
6. BA Beutler 1999 The role of tumour necrosis factor in health and disease J Rheumatol Suppl 57 16 21 10328138 1:CAS:528:DyaK1MXjtFyku78%3D (Pubitemid 29210245)
7. AA Khalil JC Hall FA Aziz P Price 2006 Tumour necrosis factor: implications for surgical patients ANZ J Surg 76 1010 1016 17054552 10.1111/j.1445-2197.2006.03921.x (Pubitemid 44581492)
8. F Bottner A Wegner W Winkelmann K Becker M Erren C Gotze 2007 Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement J Bone Joint Surg Br 89 94 99 17259424 10.1302/0301-620X.89B1.17485 1:STN:280:DC%2BD2s%2FlsFSruw%3D%3D (Pubitemid 46218420)
9. DP Mooney M O'Reilly RL Garmelli 1990 Tumor necrosis factor and wound healing Ann Sur 211 124 129 10.1097/00000658-199002000-00002 1:STN:280:DyaK3c7ks1GjsQ%3D%3D (Pubitemid 20063197)
10. AJ Busti JS Hooper CJ Amaya S Kazi 2005 Effects of perioperative anti-inflammatory immunomodulating therapy on surgical wound healing Pharmacotherapy 25 1566 1591 16232020 10.1592/phco.2005.25.11.1566 1:CAS:528:DC%2BD2MXht1Cgs7jI (Pubitemid 41566917)
11. H Pieringer U Stuby G Biesenbach 2008 The place of Methotrexate perioperatively in elective orthopaedic surgeries in patients with rheumatoid arthritis Clin Rheumatol 27 1217 1220 18414965 10.1007/s10067-008-0888-y
12. E Loza JA Martinez-Lopez L Carmona 2009 A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control Clin Exp Rheumatol 27 856 862 19917174 1:STN:280: DC%2BD1MjmtlOjsQ%3D%3D
13. CJ Edwards C Cooper D Fisher M Field TP van Staa NK Arden 2007 The importance of the disease process and disease-modifying anti rheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis Arthritis Rheum 57 1151 1157 17907232 10.1002/art.23003 (Pubitemid 47585460)
14. MF Doran CS Crowson GR Pond WM O'Fallon SE Gabriel 2002 Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum 46 2287 2293 12355475 10.1002/art.10524
15. JC Schrama B Espehaug G Hallan LB Engesaeter O Furnes LI Havelin, et al. 2010 Risk of revision for infection in primary total hip and knee arthroplasty in patients with rheumatoid arthritis compared with osteoarthritis: a prospective, population-based study on 108, 786 hip and knee joint arthroplasties from the Norwegian arthroplasty register Arthritis Care Res 62 4 473 479 10.1002/acr.20036
16. T Bongartz CS Halligan DR Osmon MS Reinalda WR Bamlet CS Crowson 2008 Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis Arthritis Rheum 59 12 1713 1720 19035425 10.1002/art.24060
17. E Jamsen H Huhtala T Puolakka T Moilanen 2009 Risk factors for infection after knee arthroplasty. A register-based analysis of 43, 149 cases J Bone Joint Surg Am 91 38 47 19122077 10.2106/JBJS.G.01686
18. S Bengtson K Knutson 1991 The infected knee arthroplasty. A 6-year follow-up of 357 cases Acta Orthop Scand 62 301 311 1882666 10.3109/ 17453679108994458 1:STN:280:DyaK3MzltlagtA%3D%3D
19. O Robertsson K Knutson S Lewold L Lidgren 2001 The Swedish knee arthroplasty register 1975-1997: an update with special emphasis on 41, 223 knees operated on in 1988-1997 Acta Orthop Scand 72 503 513 11728079 10.1080/000164701753532853 1:STN:280:DC%2BD3Mnot1SrtA%3D%3D (Pubitemid 33043591)
20. MG Wilson K Kelley TS Thornhill 1990 Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases J Bone Joint Surg Am 72 878 883 2365721 1:STN:280:DyaK3czgslOmuw%3D%3D (Pubitemid 20246892)
21. AB Wymenga JR van Horn A Theeuwes HL Muytjens TJ Slooff 1992 Perioperative factors associated with septic arthritis after arthroplasty. Prospective multicentre study of 362 knee and 2651 hip operations Acta Orthop Scand 63 665 671 1471519 1:STN:280:DyaK3s7htFSrtA%3D%3D (Pubitemid 23012680)
22. EF Berbari AD Hanssen MC Duffy JM Steckelberg DM IIstrup WS Harmsen, et al. 1998 Risk factors for prosthetic joint infection: case-control study Clin Infect Dis 27 1247 1254 9827278 10.1086/514991 1:STN:280:DyaK1M%2FksVGhtQ%3D%3D (Pubitemid 29242479)
23. SC Talwalkar DM Grennan J Gray P Johnson MJ Hayton 2005 Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery Ann Rheum Dis 64 650 651 15769927 10.1136/ard.2004.028365 1:STN:280:DC%2BD2M7jslGgsQ%3D%3D (Pubitemid 40469105)
24. D Wendling JC Balblanc A Brousse A Lohse G Lehuede P Garbuio, et al. 2005 Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures Ann Rheum Dis 64 1378 1379 16100348 10.1136/ard.2005.037762 1:STN:280: DC%2BD2MvjtFKnsw%3D%3D (Pubitemid 41206266)
25. AA den Broeder MC Creemers J Fransen E de Jong DJ de Rooij A Wymenga, et al. 2007 Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study J Rheumatol 34 4 689 695 (Pubitemid 46641372)
26. C Bibbo JW Goldberg 2004 Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy Foot Ankle Int 25 331 335 15134615 (Pubitemid 39096154)
27. Y Hirano T Kojima Y Kanayama T Shioura M Hayashi D Kida, et al. 2010 Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis Clin Rheumatol 29 495 500 20069328 10.1007/s10067-009-1346-1
28. K Kawakami K Ikari K Kawamura S Tsukahara T Iwamoto K Yano, et al. 2010 Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor alpha blockers decreases complications? Rheumatology 49 341 347 19965973 10.1093/rheumatology/kep376 1:CAS:528:DC%2BC3cXntleqsw%3D%3D
29. M Gilson L Gossec X Mariette D Gherissi MH Guyot JM Berthelot, et al. 2010 Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor alpha-blockers: a case-control study Arthritis Res Ther 12 R145 20637100 10.1186/ar3087
30. JT Giles SJ Bartlett AC Gelber S Nanda K Fontaine V Ruffing, et al. 2006 Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis Arthritis Rheum 55 333 337 16583385 10.1002/art.21841
31. A Ruyssen-Witrand L Gossec C Salliot M Luc M Duclos S Guignard, et al. 2007 Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumour necrosis factor alpha blockers Clin Exp Rheumatol 25 430 436 17631740 1:STN:280:DC%2BD2svhtlagtw%3D%3D (Pubitemid 47091020)
32. B Saleem H Keen V Goeb R Parmar S Nizam EM Hensor, et al. 2010 Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69 1636 1642 20421345 10.1136/ard.2009.117341
33. MA Quinn PG Conaghan PJ O'Connor Z Karim A Greenstein A Brown, et al. 2005 Very early treatment with Infliximab in addition to Methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after Infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum 52 27 35 15641102 10.1002/art.20712 1:CAS:528: DC%2BD2MXht1KisLY%3D (Pubitemid 40129229)
34. YP Goekoop-Ruiterman JK de Vries-Bouwstra CF Allaart D van Zeben PJ Kerstens JM Hazes, et al. 2005 Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): a randomised, controlled trial Arthritis Rheum 52 3381 3390 16258899 10.1002/art.21405 1:CAS:528:DC%2BD2MXht1KrtbfL (Pubitemid 41612204)
35. AK Brown MA Quinn Z Karim PG Conaghan CG Peterfy E Hensor, et al. 2006 Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression Arthritis Rheum 54 3761 3773 17133543 10.1002/art.22190 1:CAS:528:DC%2BD2sXktlantA%3D%3D (Pubitemid 44955876)
36. O Brocq E Millasseau C Albert C Grisot P Flory CH Roux, et al. 2009 Effect of discontinuing TNF alpha antagonist therapy in patients with remission of rheumatoid arthritis Joint Bone Spine 76 350 355 19362504 10.1016/j.jbspin.2008.11.009 1:CAS:528:DC%2BC3cXht1Clur7P
37. Y Tanaka T Takeuchi T Mimori K Saito M Nawata H Kameda, et al. 2010 Discontinuation of Infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study Ann Rheum Dis 69 1286 1291 20360136 10.1136/ard.2009.121491 1:CAS:528: DC%2BC3cXhtVSltbfI
38. KG Saag GG Teng NM Patkar J Anuntiyo C Finney JR Curtis, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762 784 18512708 10.1002/art.23721 1:CAS:528: DC%2BD1cXot1Wgs74%3D (Pubitemid 351847559)
39. T Ding J Ledingham R Luqmani S Westlake K Hyrich M Lunt, et al. 2010 BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies Rheumatology 49 2217 2219 20837498 10.1093/rheumatology/keq249a
40. Pham T, Claudepierre P, Deprez X, Fautrel B, Goupille P, Hilliquin P et al. (2005) Anti TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammation (CRI), section of the French Society of Rheumatology (Societe Francaise de Rhumatologie, SFR). Joint Bone Spine 72 (Suppl 1):S1-S58
41. N Inanc H Direskeneli 2006 Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDS in patients with rheumatoid arthritis Rheumatol Int 27 67 71 16896990 10.1007/s00296-006-0165-9 1:CAS:528:DC%2BD28XhtFaks7jM (Pubitemid 44655751)
42. J Askling CM Fored I Brandt E Baecklund L Bertilsson N Feltelius, et al. 2007 Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated TNF antagonists Ann Rheum Dis 66 1339 1344 17261532 10.1136/ard.2006.062760 (Pubitemid 47492478)
43. L Carmona MA Descalzo E Perez-pampin D Ruiz-Montesinos A Erra T Cobo, et al. 2007 All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists Ann Rheum Dis 66 880 885 17324968 10.1136/ard.2006.067660 1:CAS:528: DC%2BD2sXotlSit7s%3D (Pubitemid 46999787)
44. EG Favalli F Desiati F Atzeni P Sarzi-Puttini R Caporali FB Pallavicini, et al. 2009 Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients Autoimmun Rev 8 266 273 19022409 10.1016/j.autrev.2008.11.002 1:CAS:528:DC%2BD1MXmtVyltLY%3D
45. JB Galloway KL Hyrich LK Mercer WG Dixon B Fu AP Ustianowski, et al. 2011 Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly Rheumatology 50 124 131 20675706 10.1093/rheumatology/keq242 1:CAS:528:DC%2BC3cXhsFGkur3N
46. EC Keystone AF Kavanaugh JT Sharp H Tannenbaum Y Hua LS Teoh, et al. 2004 Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial Arthritis Rheum 50 1400 1411 15146409 10.1002/art.20217 1:CAS:528:DC%2BD2cXkvFykur4%3D (Pubitemid 38608061)
47. S Rajakulendran K Gadsby D Allen S O'Reilly C Deighton 2006 Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis Ann Rheum Dis 65 1678 1679 17105865 10.1136/ard.2006.056176 1:STN:280: DC%2BD28nmvVKktg%3D%3D (Pubitemid 44799696)
48. R Hastings T Ding S Butt K Gadsby W Zhang RJ Moots, et al. 2010 Neutropenia in patients receiving anti-tumor necrosis factor therapy Arthritis Care Res (Hoboken) 62 764 769 10.1002/acr.20037
49. Royal College of Nursing (2009) Assessing, managing and monitoring biologic therapies for inflammatory arthritis. Guidance for rheumatology practitioners. Royal College of Nursing, London
50. WG Dixon DP Symmons M Lunt KD Watson KL Hyrich 2007 Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies Arthritis Rheum 56 2896 2904 17763441 10.1002/art.22808 1:CAS:528:DC%2BD2sXht1GgtbzI (Pubitemid 47502735)
51. JR Curtis N Patkar A Xie C Martin JJ Allison M Saag, et al. 2007 Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists Arthritis Rheum 56 1125 1133 17393394 10.1002/art.22504 1:CAS:528:DC%2BD2sXltFKgsrs%3D (Pubitemid 46608637)
52. J Ledingham C Deighton 2005 Update on the British society for rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001) Rheumatology 44 157 163 15637039 10.1093/rheumatology/keh464 1:STN:280: DC%2BD2M%2FlsVSksA%3D%3D (Pubitemid 40277395)
53. LJ Kay ID Griffiths 2006 UK consultant rheumatologists' access to biological agents and views on the BSR biologic register Rheumatology 45 1376 1379 17040892 10.1093/rheumatology/kel333 1:CAS:528:DC%2BD28XhtFeisbrM (Pubitemid 44605472)
54. LW Moreland SB Cohen SW Baumgartner EA Tindall K Bulpitt R Martin, et al. 2001 Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis J Rheumatol 28 1238 1244 11409115 1:CAS:528:DC%2BD3MXkvVOhu7g%3D (Pubitemid 32510493)
55. MC Genovese JM Bathon RM Fleischmann LW Moreland RW Martin JB Whitmore, et al. 2005 Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis J Rheumatol 32 1232 1242 15996057 1:CAS:528:DC%2BD2MXnsl2nsrY%3D (Pubitemid 40995375)
56. FC Breedveld MH Weisman AF Kavanaugh SB Cohen K Pavelka R van Vollenhoven, et al. 2006 The PREMIER study: a multicentre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26 37 16385520 10.1002/art.21519 1:CAS:528:DC%2BD28XhsVens74%3D (Pubitemid 43122183)
57. GC Gardner MH Weisman 1990 Pyarthrosis in patients with rheumatoid arthritis: a report of 13 cases and a review of the literature from the past 40 years Am J Med 88 503 511 2186625 10.1016/0002-9343(90)90430-L 1:STN:280:DyaK3c3kslCjug%3D%3D (Pubitemid 20168727)
58. JJ Dubost I Fis P Denis R Lopitaux M Soubrier JM Ristori, et al. 1993 Polyarticular septic arthritis Medicine (Baltimore) 72 296 310 1:STN:280:DyaK2c%2FhvVGrsw%3D%3D (Pubitemid 23360477)
59. WD Blackburn Jr TL Dunn GS Alarcon 1986 Infection versus disease activity in rheumatoid arthritis: eight years' experience South Med J 79 1238 1241 3764520 10.1097/00007611-198610000-00011
60. M Favero F Schiavon L Riato V Carraro L Punzi 2008 Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings Autoimmun Rev 8 59 61 18706527 10.1016/j.autrev.2008.07.018 1:STN:280: DC%2BD1cnmvFansw%3D%3D
61. MF Doran CS Crowson GR Pond WM O'Fallon SE Gabriel 2002 Predictors of infection in rheumatoid arthritis Arthritis Rheum 46 2294 2300 12355476 10.1002/art.10529
62. Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T et al (2004) Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with Infliximab or immunosuppressive therapy. Am J Gastroenterol 99: 878-883 (Pubitemid 39090217)
63. L Marchal G D'Haens G Van Assche S Vermeire M Noman M Ferrante, et al. 2004 The risk of post-operative complications associated with Infliximab therapy for Crohn's disease: a controlled cohort study Aliment Pharmacol Ther 19 749 754 15043515 10.1111/j.1365-2036.2004.01904.x 1:CAS:528:DC%2BD2cXktVGnu7Y%3D (Pubitemid 38496640)
64. DR Topstad R Panaccione JA Heine DR Johnson AR MacLean WD Buie 2003 Combined seton placement, Infliximab infusion, and maintenance immunosuppressive improve healing rate in fistulizing anorectal Crohn's disease: a singer centre experience Dis Colon Rectum 46 577 583 12792431 10.1007/s10350-004-6611-4 (Pubitemid 36576412)
65. Nasir BS, Dozois EJ, Cima RR, Pemberton JH, Wolff BG, Sandborn WJ et al (2010) Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease. J Gastrointest Surg 14:1859-1865